0
Several new studies in lung cancer have opened their doors recently. Is one of your patients eligible to participate?
Resected stage II, IIIA, or IIIB with nodal involvement non–small cell lung cancer (NSCLC). Adult patients with this type of cancer can join a randomized, controlled, phase 3 study assessing whether an investigational drug called V940 added to pembrolizumab (Keytruda) delays cancer recurrence better than pembrolizumab alone.
V940 is an individualized neoantigen therapy designed to generate T-cell antitumor responses targeted to a patient’s specific mutation profile.
V940 plus pembrolizumab showed a trend toward longer recurrence-free survival vs pembrolizumab alone in a recent phase 2 study in melanoma (hazard ratio, 0.561; P = .053).
In the current trial, one group of participants will receive intramuscular injections of V940 every 3 weeks plus intravenous (IV) pembrolizumab every 6 weeks for up to approximately 1 year or until disease recurrence or unacceptable toxicity, whichever happens first. The other people in the trial will be on the same schedule, with a placebo replacing V940.
Centers in Florida, Georgia, Kentucky, Montana, New Jersey, New York, North Dakota, and six other countries started recruiting for the trial’s 868 participants in December 2023. Disease-free survival is the primary endpoint. Overall survival over approximately 12 years and quality of life (QoL) are secondary endpoints. More details at clinicaltrials.gov
Metastatic NSCLC with a programmed cell death ligand 1 (PD-L1)-tumor proportion score of > 50%. Adults in this clinical situation are eligible for a randomized, open-label, phase 3 trial to determine whether an experimental antibody-drug conjugate called MK-2870 added to standard pembrolizumab prolongs survival.
MK-2870 delivers a cytotoxin to cancer cells by binding to trophoblast cell-surface antigen 2, known to promote tumor cell growth and metastasis. For up to 2 years, half of participants will receive MK-2870 by IV every 2 weeks plus IV pembrolizumab every 6 weeks. The other group will receive only pembrolizumab.In December 2023, study sites in Georgia, Minnesota, Mississippi, Nevada, Oregon, Australia, Denmark, Taiwan, and Turkeystarted seeking the trial’s 614 participants. Overall survival over approximately 4 years is the primary endpoint; QoL is a secondary endpoint. More details at […]
Oklahoma’s Own Focus On Kids: Health Experts Alarmed By Rising Teen Marijuana Usage
As the marijuana industry continues to grow in Oklahoma, state
